Exelixis Balance Sheet Health
Financial Health criteria checks 6/6
Exelixis has a total shareholder equity of $2.3B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.9B and $678.4M respectively. Exelixis's EBIT is $170.9M making its interest coverage ratio -2. It has cash and short-term investments of $995.3M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -2x |
| Cash | US$995.30m |
| Equity | US$2.26b |
| Total liabilities | US$678.45m |
| Total assets | US$2.94b |
Recent financial health updates
No updates
Recent updates
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22
Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued
May 30Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise
Oct 18Exelixis: Efforts Continue To Diversify The Pipeline
Sep 15Exelixis, Teva fight over Cabometyx generic again
Sep 06Exelixis Needs To Move Away From Its Overdependence On Cabozantinib
Aug 03Exelixis again sues MSN Pharmaceuticals over Cabometyx generic
Jul 19Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs
Jul 07Exelixis: Becoming A Giant Pharma
May 18Exelixis: Beyond The Cabozantinib Franchise
Apr 21Financial Position Analysis
Short Term Liabilities: EXEL's short term assets ($1.3B) exceed its short term liabilities ($394.3M).
Long Term Liabilities: EXEL's short term assets ($1.3B) exceed its long term liabilities ($284.2M).
Debt to Equity History and Analysis
Debt Level: EXEL is debt free.
Reducing Debt: EXEL had no debt 5 years ago.
Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.